Daxor Corporation

281 articles with Daxor Corporation

• Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients

  3/23/2023

  Daxor Corporation today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients.

• New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

  3/23/2023

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients.

• Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022

  3/2/2023

  Daxor Corporation, the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December 31, 2022.

• Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update

  3/1/2023

  Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will report financial results for the full year ending December 31, 2022 on Wednesday, March 1, 2023 after the stock market close, and host a conference call on Thursday, March 2, 2023 at approximately 9:00 a.m. EST.

• Daxor Corporation Appoints Linda Cooper, Vice President Project Management

  2/17/2023

  Daxor Corporation, the global leader in blood volume measurement technology, announces the appointment of Linda Cooper as Vice President of Project Management.

• Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member

  1/19/2023

  Daxor Corporation, the global leader in blood volume measurement technology, announces joining the Heart Failure Society of America as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure.

• Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress

  1/13/2023

  Daxor Corporation today announces it will be presenting at the Society for Critical Care Medicine (SCCM) 2023 Critical Care Congress at the Moscone Center In San Francisco, CA from January 21 through the 24, 2023.

• Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

  1/3/2023

  Daxor Corporation (Nasdaq: DXR) today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary artery diastolic pressure (PADP) monitor - two key metrics of cardiovascular congestion.

• Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option

  11/17/2022

  DAXOR CORPORATION, the global leader in blood volume measurement technology, announced the closing of its previously announced underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share.

• Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering

  11/15/2022

  DAXOR CORPORATION, the global leader in blood volume measurement technology, announced the pricing of an underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share.

• Daxor Corporation Announces Launch of Proposed Underwritten Public Offering - November 14, 2022

  11/14/2022

  DAXOR CORPORATION, the global leader in blood volume measurement technology, announced that it has commenced an underwritten public offering of shares of its common stock.

• Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs

  11/10/2022

  Daxor Corporation announces Daxor’s BVA-100 diagnostic will be featured in a MedAxiom Academy webinar - Best Practices for Using Blood Volume Analysis to Reduce Heart Failure LOS, Readmissions, Mortality and Costs on November 17, 2022, at 1pm ET.

• Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

  11/3/2022

  Daxor Corporation announces a new study in the prestigious Journal of Cardiac Failure demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure.

• Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022

  10/31/2022

  Daxor Corporation, the global leader in blood volume measurement technology, announces it will be attending the American Heart Association Scientific Sessions at McCormick Place Convention Center in Chicago, IL from November 5-7th, 2022.

• Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting

  10/5/2022

  Daxor Corporation announces that a scientific session titled “Debating Volume-based versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure” was held during the Heart Failure Society of America Annual Scientific Meeting on October 3rd, 2022, in Washington, DC.

• Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting

  10/4/2022

  Daxor Corporation, the global leader in blood volume measurement technology, announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure.

• Daxor Corporation to Exhibit and Present at the Medaxiom Cardiovascular Transforum Conference Fall’22 to Advance Awareness and Further Adoption of Daxor’s Blood Volume Diagnostic (BVA-100®)

  10/4/2022

  Daxor Corporation, the global leader in blood volume measurement technology, announces it will be exhibiting for the first time at the MedAxiom CV Transforum Fall’22 Conference being held at the JW Marriott in Austin, TX from October 6-8, 2022.

• New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures

  10/3/2022

  Daxor Corporation, the global leader in blood volume measurement technology, announces new data from Duke Heart validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for heart failure patients.

• New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%

  10/3/2022

  Daxor Corporation, the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic blood test in reducing hospital length of stay (LOS) for heart failure (HF) patients.

• New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care

  10/3/2022

  Daxor Corporation, the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test for heart failure patients.